Bal Pharma posts Q3 FY2023 profit at Rs. 59.16 lakhs
The company has reported total income of Rs.77.0791 crores during the period ended December 31, 2022 as compared to Rs.69.9191 crores during the period ended December 31, 2021.
The company has reported total income of Rs.77.0791 crores during the period ended December 31, 2022 as compared to Rs.69.9191 crores during the period ended December 31, 2021.
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Subscribe To Our Newsletter & Stay Updated